We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01658501
Recruitment Status : Completed
First Posted : August 7, 2012
Last Update Posted : December 7, 2015
Information provided by (Responsible Party):
PhaseBio Pharmaceuticals Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : July 2013
  Study Completion Date : July 2013
  Certification or Request for Extension to Delay Results Submission: October 28, 2014